Cover Image

Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020

Notice
This publication has been discontinued on August 30, 2013.

Abstract

Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020

Summary

GlobalData, the industry analysis specialist, has released its new report, "Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020". The report is an essential source of information and analysis on the global type 2 diabetes therapeutics market. The report provides comprehensive information on type 2 diabetes, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global type 2 diabetes therapeutics market. It analyses the treatment usage patterns in the global type 2 diabetes therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global type 2 diabetes sector. It quantifies the unmet need in the global type 2 diabetes therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData analysis shows that the global type 2 diabetes therapeutics market was worth $23.7 billion in 2011. Between 2002 and 2011, the market grew at a rate of 11.8%. By 2020, the market is expected to be worth $45.1 billion, indicating a Compound Annual Growth Rate (CAGR) of 7.4% between 2011 and 2020.

The global type 2 diabetes therapeutics market is very attractive and has primarily been driven by the growth in patient volume and the annual cost of therapy. Patient volume has been driven by the increased incidence and prevalence of diabetes and the growth in treatment usage patterns, such as the diseased population, the treatment-seeking population, the diagnosed population and the prescription population. The annual cost of type 2 diabetes therapy was driven by the uptake of newly approved drugs, such as Actos (pioglitazone) and Avandia (rosiglitazone) until 2006 and the launch of new therapies, such as Levemir (insulin detemir), Byetta (exenatide), Januvia (sitagliptin), and Victoza (liraglutide). The annual cost of therapy was also driven by the increased use of multiple drugs per patient and the adoption of combination therapies, such as Actoplusmet (pioglitazone and metformin), Avandamet (rosiglitazone and metformin), Janumet (sitagliptin and metformin) and Duetact (pioglitazone and glimepiride) in the first-line and second-line treatment of type 2 diabetes patients.

Metformin, alone or in combination with other oral agents, has become the standard of care for the first-line treatment of type 2 diabetes patients. Similarly, metformin in combination with DPP4 inhibitors or GLP-1 analogs has become one of the most commonly prescribed treatment options for type 2 diabetes. In 2011, within the countries analyzed in this report (the US, EU5, Japan and BRIC countries), the US was the leading market with an estimated market share of 52.7%. Japan was the second leading market with an approximate market share of 12.8%, closely followed by Germany with an approximate market share of 7.5%. In 2011, Lantus was the leading drug, with approximate sales worth $3.6 billion and a market share of 18%. Januvia/Janumet, the DPP4 inhibitor was the second leading drug, with approximate sales of $3.4 billion and a market share of 17.1%. Actos was the third leading drug, with an approximate sales value of $1.9 billion and a market share of 9.6%.

Scope

The scope of the report includes -

  • An overview of type 2 diabetes which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized global type 2 diabetes therapeutics market revenue, annual cost of therapy and treatment usage patterns data by stage of the disease from 2002 to 2011, forecast for 9 years to 2020.
  • Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China
  • Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
  • Competitor assessment including drug launch analysis and drug sales forecasts.
  • Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities, product positioning and drug sales forecast.
  • Analysis of unmet need in the market and target product profile including opportunity for target product.
  • Technology trends analytic framework to assess strength of pipeline.
  • Pipeline analysis data providing a split by stage of the disease and line of therapy across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include SGLT-2 inhibitors, 11β HSD inhibitors, CCR2 antagonists, selective inhibitors of fructose 1, 6-bisphosphatase, immunomodulators, cortisol synthesis inhibitors, interleukin-1β antagonists, gastrin-releasing peptide (GRP) receptor agonists, GPR 119 agonists, TLR-4 receptor agonists, FXR antagonists and GSK-3 inhibitors.
  • Clinical trials mapping for type 2 diabetes in different regions.
  • An overview of the most promising drugs' including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forcasts to 2020.
  • Analysis of the current and future market competition in the global type 2 diabetes therapeutics market.
  • Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Astellas Pharma Inc, Takeda Pharmaceuticals, Boehringer Ingelheim, Novartis, Sanofi, J&J and Hoffmann La Roche.
  • Analysis of licensing agreements during 2008-2011 in the type 2 diabetes therapeutics market. M&A analysis which includes M&A deals by size and geography.
  • Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
  • Direct quotes from key opinion leaders (KOL) or physicians in the type 2 diabetes therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

  • Develop business strategies and perform superior market quantification analysis by
  • Understanding the trends shaping and driving the global type 2 diabetes therapeutics market.
  • Understanding treatment preferences of physicians in disease state and across treatment flow.
  • Accessing market sizing, forecasts and quantified growth opportunities in the global type 2 diabetes therapeutics market till 2020.
  • Quantifying patient population in the global type 2 diabetes market to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
  • Performing benchmarking analysis and growth opportunities against currently marketed products
  • Identifying market entry points based on safety, efficacy, and pricing parameters.
  • Assessing competitiveness of products in market by understanding the strength and weakness of current competition.
  • Develop and design your in-licensing and out-licensing strategies by
  • Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
  • Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
  • Track drug sales in the global type 2 diabetes therapeutics market from 2002 to 2020.
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
  • What's the next big thing in the global type 2 diabetes therapeutics market landscape? Identify, understand and capitalize.

Keywords

Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action, oncology, cancer, treatment guideline, target product profile, clinician's endpoints, disease overview, colorectal cancer drug sales, US colorectal cancer market, UK colorectal cancer market, France colorectal cancer market, Germany colorectal cancer market, Italy colorectal cancer market, Spain colorectal cancer market, Japan colorectal cancer market, BRIC colorectal cancer market, Brazil, Russia, India, China

TOC

1 Table of Contents

1 Table of Contents 3

  • 1.1 List of Tables 5
  • 1.2 List of Figures 9

2 Disease Overview 15

  • 2.1 Overview 15
  • 2.2 Epidemiology 15
  • 2.3 Economic Impact of Diabetes 17
  • 2.4 Etiology 17
  • 2.5 Symptoms 18
  • 2.6 Diagnosis 18
  • 2.7 Pathology 20
  • 2.8 Treatment 21
  • 2.9 Treatment Guidelines 26
  • 2.10 GlobalData In-Depth Report Guidance 27

3 Market Characterization 28

  • 3.1 Global 28
  • 3.2 The US 55
  • 3.3 The UK 77
  • 3.4 Germany 99
  • 3.5 France 122
  • 3.6 Italy 143
  • 3.7 Spain 164
  • 3.8 Japan 184
  • 3.9 Brazil 204
  • 3.10 India 219
  • 3.11 China 234
  • 3.12 Russia 248
  • 3.13 Key Takeaway 263

4 Type 2 Diabetes Therapeutics - Opportunity and Unmet Need 264

  • 4.1 Unmet Need 264
  • 4.2 Opportunity for Target Products 266
  • 4.3 Target Product Profile 267
  • 4.4 Key Takeaway 268

5 Type 2 Diabetes Therapeutics - Competitive Assessment 269

  • 5.1 Strategic Competitive Assessment 269
  • 5.2 Launch Analysis and Sales Forecasts 273
  • 5.3 Product Profiles 274
  • 5.4 Recently Launched or Approved Products in the Market 372
  • 5.5 Partners in Development - Marketed Products 387
  • 5.6 Key Takeaway 387

6 Type 2 Diabetes Therapeutics - Pipeline Assessment 388

  • 6.1 Overview 388
  • 6.2 Pipeline Analysis by Phase of Development 388
  • 6.3 Pipeline by Mechanism of Action 388
  • 6.4 Strategic Pipeline Assessment 390
  • 6.5 Trends in Type 2 Diabetes Pipeline 392
  • 6.6 Type 2 Diabetes Pipeline - Regulatory Filing 395
  • 6.7 Type 2 Diabetes Pipeline - Phase III 396
  • 6.8 Type 2 Diabetes Pipeline - Phase II 397
  • 6.9 Type 2 Diabetes Pipeline - Phase I 400
  • 6.10 Type 2 Diabetes Pipeline - Preclinical and Discovery 403
  • 6.11 Most Promising Drug Profiles 407
  • 6.12 Partners in Development - Pipeline Products 437
  • 6.13 Key Takeaway 444

7 Type 2 Diabetes Therapeutics - Clinical Trials Mapping 445

  • 7.1 Clinical Trials 445
  • 7.2 Patient Recruitment 452

8 Type 2 Diabetes Therapeutics - Implications for Future Market Competition 453

  • 8.1 Key Events Impacting the Future Market 453
  • 8.2 Market Impact Analysis 453
  • 8.3 Future Market Scenario 454
  • 8.4 Company Analysis 455

9 Type 2 Diabetes Therapeutics - Future Market Players 457

  • 9.1 Introduction 457
  • 9.2 Novo Nordisk 457
  • 9.3 Amylin Pharmaceuticals 461
  • 9.4 Takeda Pharmaceuticals 465
  • 9.5 Boehringer Ingelheim 468
  • 9.6 Eli Lilly and Company 471
  • 9.7 GlaxoSmithKline 474
  • 9.8 Novartis 477
  • 9.9 Sanofi 480
  • 9.10 F. Hoffmann La Roche 483
  • 9.11 Bristol-Myers Squibb 485
  • 9.12 Johnson & Johnson (J&J) 488
  • 9.13 Astellas Pharma Inc. 495

10 Deals Analysis 502

  • 10.1 Key Highlights 502
  • 10.2 Key Deals Analysis 502
  • 10.3 Deals Analysis by Geography 504
  • 10.4 Deals Analysis by Deal Size 504

11 Type 2 Diabetes Therapeutics - Expert Opinion 505

  • 11.1 Expert Opinion 505

12 Type 2 Diabetes Therapeutics - Appendix 507

  • 12.1 Definitions 507
  • 12.2 Acronyms 507
  • 12.3 Research Methodology 509
  • 12.4 Contact Us 513
  • 12.5 Disclaimer 513
  • 12.6 Bibliography 513

List of Tables

1.1 List of Tables

  • Table 1: Type 2 Diabetes, Global, Prevalence Estimates for the 20-79 Age Group (million), 2000-2030 19
  • Table 2: Type 2 Diabetes, Top 10 Countries, Prevalence (million), 2010 and 2030 19
  • Table 3: Type 2 Diabetes, Top 10 Countries, Health Expenditures ($bn), 2011 20
  • Table 4: Type 2 Diabetes Therapeutics Market, Fasting Plasma Glucose Tests 21
  • Table 5: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn), 2002-2011 31
  • Table 6: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn) by Country, 2002-2011 33
  • Table 7: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2011 35
  • Table 8: Type 2 Diabetes Therapeutics Market, Global, Patient Volume (million), 2002-2011 37
  • Table 9: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2011 39
  • Table 10: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn), 2011-2020 44
  • Table 11: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn) by Country, 2011-2020 45
  • Table 12: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2020 47
  • Table 13: Type 2 Diabetes Therapeutics Market, Global, Patient Volume (million), 2011-2020 49
  • Table 14: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2020 51
  • Table 15: Type 2 Diabetes Therapeutics Major Markets, Drug Sales ($m), 2002-2011 56
  • Table 16: Type 2 Diabetes Therapeutics Major Markets, Drug Sales ($m), 2012-2020 57
  • Table 17: Type 2 Diabetes Therapeutics Market, The US, Sales Value ($bn), 2002-2011 58
  • Table 18: Type 2 Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2011 59
  • Table 19: Type 2 Diabetes Therapeutics Market, The US, Patient Volume (million), 2002-2011 61
  • Table 20: Type 2 Diabetes Therapeutics Market, The US, Treatment Usage Patterns (million), 2002-2011 63
  • Table 21: Type 2 Diabetes Therapeutics Market, The US, Sales Value ($bn), 2011-2020 68
  • Table 22: Type 2 Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2011-2020 69
  • Table 23: Type 2 Diabetes Therapeutics Market, The US, Patient Volume (million), 2011-2020 70
  • Table 24: Type 2 Diabetes Therapeutics Market, The US, Treatment Usage Patterns (million), 2011-2020 72
  • Table 25: Type 2 Diabetes Therapeutics Market, US, Drug Sales ($m), 2002-2011 77
  • Table 26: Type 2 Diabetes Therapeutics Market, US, Drug Sales ($m), 2012-2020 78
  • Table 27: Type 2 Diabetes Therapeutics Market, The UK, Sales Value ($m), 2002-2011 80
  • Table 28: Type 2 Diabetes Therapeutics Market, The UK, Annual Cost of Therapy ($), 2002-2011 81
  • Table 29: Type 2 Diabetes Therapeutics Market, The UK, Patient Volume (million), 2002-2011 83
  • Table 30: Type 2 Diabetes Therapeutics Market, The UK, Treatment Usage Patterns (million), 2002-2011 84
  • Table 31: Type 2 Diabetes Therapeutics Market, The UK, Sales Value ($m), 2011-2020 89
  • Table 32: Type 2 Diabetes Therapeutics Market, The UK, Annual Cost of Therapy ($), 2011-2020 90
  • Table 33: Type 2 Diabetes Therapeutics Market, The UK, Patient Volume (million), 2011-2020 92
  • Table 34: Type 2 Diabetes Therapeutics Market, The UK, Treatment Usage Patterns (million), 2011-2020 94
  • Table 35: Type 2 Diabetes Therapeutics Market, The UK, Drug Sales ($m), 2002-2011 99
  • Table 36: Type 2 Diabetes Therapeutics Market,The UK, Drug Sales ($m), 2012-2020 100
  • Table 37: Type 2 Diabetes Therapeutics Market, Germany, Sales Value ($m), 2002-2011 102
  • Table 38: Type 2 Diabetes Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002-2011 103
  • Table 39: Type 2 Diabetes Therapeutics Market, Germany, Patient Volume (million), 2002-2011 105
  • Table 40: Type 2 Diabetes Therapeutics Market, Germany, Treatment Usage Patterns (million), 2002-2011 107
  • Table 41: Type 2 Diabetes Therapeutics Market, Germany, Sales Value ($m), 2011-2020 112
  • Table 42: Type 2 Diabetes Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011-2020 113
  • Table 43: Type 2 Diabetes Therapeutics Market, Germany, Patient Volume (million), 2011-2020 115
  • Table 44: Type 2 Diabetes Therapeutics Market, Germany, Treatment Usage Patterns (million), 2011-2020 117
  • Table 45: Type 2 Diabetes Therapeutics Market, Germany, Drug Sales ($m), 2002-2011 122
  • Table 46: Type 2 Diabetes Therapeutics Market, Germany, Drug Sales ($m), 2012-2020 123
  • Table 47: Type 2 Diabetes Therapeutics Market, France, Sales Value ($m), 2002-2011 125
  • Table 48: Type 2 Diabetes Therapeutics Market, France, Annual Cost of Therapy ($), 2002-2011 126
  • Table 49: Type 2 Diabetes Therapeutics Market, France, Patient Volume (million), 2002-2011 128
  • Table 50: Type 2 Diabetes Therapeutics Market, France, Treatment Usage Patterns (million), 2002-2011 129
  • Table 51: Type 2 Diabetes Therapeutics Market, France, Sales Value ($m), 2011-2020 134
  • Table 52: Type 2 Diabetes Therapeutics Market, France, Annual Cost of Therapy ($), 2011-2020 135
  • Table 53: Type 2 Diabetes Therapeutics Market, France, Patient Volume (million), 2011-2020 136
  • Table 54: Type 2 Diabetes Therapeutics Market, France, Treatment Usage Patterns (million), 2011-2020 138
  • Table 55: Type 2 Diabetes Therapeutics Market, France, Drug Sales ($m), 2002-2011 143
  • Table 56: Type 2 Diabetes Therapeutics Market, France, Drug Sales ($m), 2012-2020 144
  • Table 57: Type 2 Diabetes Therapeutics Market, Italy, Sales Value ($m), 2002-2011 146
  • Table 58: Type 2 Diabetes Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002-2011 147
  • Table 59: Type 2 Diabetes Therapeutics Market, Italy, Patient Volume (million), 2002-2011 148
  • Table 60: Type 2 Diabetes Therapeutics Market, Italy, Treatment Usage Patterns (million), 2002-2011 150
  • Table 61: Type 2 Diabetes Therapeutics Market, Italy, Sales Value ($m), 2011-2020 155
  • Table 62: Type 2 Diabetes Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011-2020 156
  • Table 63: Type 2 Diabetes Therapeutics Market, Italy, Patient Volume (million), 2011-2020 157
  • Table 64: Type 2 Diabetes Therapeutics Market, Italy, Treatment Usage Patterns (million), 2011-2020 159
  • Table 65: Type 2 Diabetes Therapeutics Market, Italy, Drug Sales ($m), 2002-2011 164
  • Table 66: Type 2 Diabetes Therapeutics Market, Italy, Drug Sales ($m), 2012-2020 165
  • Table 67: Type 2 Diabetes Therapeutics Market, Spain, Sales Value ($m), 2002-2011 167
  • Table 68: Type 2 Diabetes Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002-2011 168
  • Table 69: Type 2 Diabetes Therapeutics Market, Spain, Patient Volume (million), 2002-2011 169
  • Table 70: Type 2 Diabetes Therapeutics Market, Spain, Treatment Usage Patterns (million), 2002-2011 170
  • Table 71: Type 2 Diabetes Therapeutics Market, Spain, Sales Value ($m), 2011-2020 175
  • Table 72: Type 2 Diabetes Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011-2020 176
  • Table 73: Type 2 Diabetes Therapeutics Market, Spain, Patient Volume (million), 2011-2020 177
  • Table 74: Type 2 Diabetes Therapeutics Market, Spain, Treatment Usage Patterns (million), 2011-2020 179
  • Table 75: Type 2 Diabetes Therapeutics Market, Spain, Drug Sales ($m), 2002-2011 184
  • Table 76: Type 2 Diabetes Therapeutics Market, Spain, Drug Sales ($m), 2012-2020 185
  • Table 77: Type 2 Diabetes Therapeutics Market, Japan, Sales Value ($m), 2002-2011 187
  • Table 78: Type 2 Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2011 188
  • Table 79: Type 2 Diabetes Therapeutics Market, Japan, Patient Volume (million), 2002-2011 189
  • Table 80: Type 2 Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (million), 2002-2011 190
  • Table 81: Type 2 Diabetes Therapeutics Market, Japan, Sales Value ($m), 2011-2020 195
  • Table 82: Type 2 Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2020 196
  • Table 83: Type 2 Diabetes Therapeutics Market, Japan, Patient Volume (million), 2011-2020 197
  • Table 84: Type 2 Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (million), 2011-2020 199
  • Table 85: Type 2 Diabetes Therapeutics Market, Japan, Drug Sales ($m), 2002-2011 204
  • Table 86: Type 2 Diabetes Therapeutics Market, Japan, Drug Sales ($m), 2012-2020 205
  • Table 87: Type 2 Diabetes Therapeutics Market, Brazil, Sales Value ($m), 2002-2011 207
  • Table 88: Type 2 Diabetes Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002-2011 208
  • Table 89: Type 2 Diabetes Therapeutics Market, Brazil, Patient Volume (million), 2002-2011 209
  • Table 90: Type 2 Diabetes Therapeutics Market, Brazil, Treatment Usage Patterns (million), 2002-2011 210
  • Table 91: Type 2 Diabetes Therapeutics Market, Brazil, Sales Value ($m), 2011-2020 215
  • Table 92: Type 2 Diabetes Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011-2020 216
  • Table 93: Type 2 Diabetes Therapeutics Market, Brazil, Patient Volume, (million) 2011-2020 217
  • Table 94: Type 2 Diabetes Therapeutics Market, Brazil, Treatment Usage Patterns (million), 2011-2020 219
  • Table 95: Type 2 Diabetes Therapeutics Market, India, Sales Value ($m), 2002-2011 222
  • Table 96: Type 2 Diabetes Therapeutics Market, India, Annual Cost of Therapy ($), 2002-2011 223
  • Table 97: Type 2 Diabetes Therapeutics Market, India, Patient Volume (million), 2002-2011 224
  • Table 98: Type 2 Diabetes Therapeutics Market, India, Treatment Usage Patterns (million), 2002-2011 225
  • Table 99: Type 2 Diabetes Therapeutics Market, India, Sales Value ($m), 2011-2020 230
  • Table 100: Type 2 Diabetes Therapeutics Market, India, Annual Cost of Therapy ($), 2011-2020 231
  • Table 101: Type 2 Diabetes Therapeutics Market, India, Patient Volume (million), 2011-2020 232
  • Table 102: Type 2 Diabetes Therapeutics Market, India, Treatment Usage Patterns (million), 2011-2020 234
  • Table 103: Type 2 Diabetes Therapeutics Market, China, Sales Value ($m), 2002-2011 237
  • Table 104: Type 2 Diabetes Therapeutics Market, China, Annual Cost of Therapy ($), 2002-2011 238
  • Table 105: Type 2 Diabetes Therapeutics Market, China, Patient Volume (million) 2002-2011 239
  • Table 106: Type 2 Diabetes Therapeutics Market, China, Treatment Usage Patterns (million), 2002-2011 240
  • Table 107: Type 2 Diabetes Therapeutics Market, China, Sales Value ($m), 2011-2020 245
  • Table 108: Type 2 Diabetes Therapeutics Market, China, Annual Cost of Therapy ($), 2011-2020 246
  • Table 109: Type 2 Diabetes Therapeutics Market, China, Patient Volume (million), 2011-2020 247
  • Table 110: Type 2 Diabetes Therapeutics Market, China, Treatment Usage Patterns (million), 2011-2020 249
  • Table 111: Type 2 Diabetes Therapeutics Market, Russia, Sales Value ($m), 2002-2011 252
  • Table 112: Type 2 Diabetes Therapeutics Market, Russia, Annual Cost of Therapy ($), 2002-2011 253
  • Table 113: Type 2 Diabetes Therapeutics Market, Russia, Patient Volume (million), 2002-2011 254
  • Table 114: Type 2 Diabetes Therapeutics Market, Russia, Treatment Usage Patterns (million), 2002-2011 255
  • Table 115: Type 2 Diabetes Therapeutics Market, Russia, Sales Value ($m), 2011-2020 260
  • Table 116: Type 2 Diabetes Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011-2020 261
  • Table 117: Type 2 Diabetes Therapeutics Market, Russia, Patient Volume (million), 2011-2020 262
  • Table 118: Type 2 Diabetes Therapeutics Market, Russia, Treatment Usage Patterns (million), 2011-2020 264
  • Table 119: Type 2 Diabetes Therapeutics Market, Global, Characteristics of Ideal Drug that Would Satisfy the Unmet Needs, 2011 270
  • Table 120: Type 2 Diabetes Therapeutics Market, Global, Description of Ideal Drug that Would Satisfy the Unmet Needs, 2011 270
  • Table 121: Type 2 Diabetes Therapeutics Market, Global, Benchmarking Major Marketed Products, 2011 277
  • Table 122: Type 2 Diabetes, Global, Actos, Adverse Effects Incidence, 2011 281
  • Table 123: Type 2 Diabetes Therapeutics Market, Global, Avandia, Cardiovascular Adverse Effects Incidence, 2011 285
  • Table 124: Type 2 Diabetes Therapeutics Market, Global, Metformin, Adverse Effects Incidence, 2011 289
  • Table 125: Type 2 Diabetes Therapeutics Market, Global, Amaryl, Adverse Effects Incidence, 2011 293
  • Table 126: Type 2 Diabetes Therapeutics Market, Global, Amaryl, Regulatory Approval, 2011 294
  • Table 127: Type 2 Diabetes Therapeutics Market, Global, Glyburide, Clinical Study Details, 2011 298
  • Table 128: Type 2 Diabetes Therapeutics Market, Global, Glyburide, Clinical Study Details, 2011 298
  • Table 129: Type 2 Diabetes Therapeutics Market, Global, Glipizide, Clinical Study Details, 2011 302
  • Table 130: Type 2 Diabetes Therapeutics Market, Global, Precose, Clinical Study Details, 2011 305
  • Table 131: Type 2 Diabetes Therapeutics Market, Global, Glyset, Clinical Study Details, 2011 309
  • Table 132: Type 2 Diabetes Therapeutics Market, Global, Glyset, Regulatory Approval, 2011 310
  • Table 133: Type 2 Diabetes Therapeutics Market, Global, Basen, Regulatory Approval, 2011 313
  • Table 134: Type 2 Diabetes Therapeutics Market, Global, Januvia, Adverse Effects Incidence, 2011 316
  • Table 135: Type 2 Diabetes Therapeutics Market, Global, Januvia, Clinical Study Details as Monotherapy, 2011 317
  • Table 136: Type 2 Diabetes Therapeutics Market, Global, Januvia, Clinical Study Details as Add-on to Metformin and Rosiglitazone, 2011 318
  • Table 137: Type 2 Diabetes Therapeutics Market, Global, Januvia, Clinical Study Details as Add-on to Metformin, 2011 319
  • Table 138: Type 2 Diabetes Therapeutics Market, Global, Januvia, Clinical Study Details as Add-on to Pioglitaozone, 2011 320
  • Table 139: Type 2 Diabetes Therapeutics Market, Global, Januvia, Regulatory Approval, 2011 321
  • Table 140: Type 2 Diabetes Therapeutics Market, Global, Onglyza, Adverse Effects Incidence, 2011 325
  • Table 141: Type 2 Diabetes Therapeutics Market, Global, Galvus, Efficacy Monotherapy Trial, 2011 330
  • Table 142: Type 2 Diabetes Therapeutics Market, Global, Galvus, Efficacy Combination Trial, 2011 331
  • Table 143: Type 2 Diabetes Therapeutics Market, Global, Byetta, Efficacy, 2011 339
  • Table 144: Type 2 Diabetes Therapeutics Market, Global, Byetta, Adverse Effects Incidence, 2011 340
  • Table 145: Type 2 Diabetes Therapeutics Market, Global, Victoza, Adverse Effects Incidence, 2011 345
  • Table 146: Type 2 Diabetes Therapeutics Market, Global, Humalog, Clinical Study Details as a Monotherapy, 2011 357
  • Table 147: Type 2 Diabetes Therapeutics Market, Global, Humalog, Comparative Clinical Study Details in Combination with a Sulfonylurea, 2011 358
  • Table 148: Type 2 Diabetes Therapeutics Market, Global, Humulin, Regulatory Approval, 2011 361
  • Table 149: Type 2 Diabetes Therapeutics Market, Global, Novolog, Clinical Study Details, 2011 365
  • Table 150: Type 2 Diabetes Therapeutics Market, Global, Novolog, Clinical Study Details as a Pump Therapy, 2011 365
  • Table 151: Type 2 diabetes Therapeutics Market, Global, Novolog, Regulatory Approvals, 2011 366
  • Table 152: Type 2 Diabetes Therapeutics Market, Global, Apidra, Adverse Effects Incidence, 2011 368
  • Table 153: Type 2 Diabetes Therapeutics Market, Global, Apidra, Clinical Study Details, 2011 369
  • Table 154: Type 2 Diabetes Therapeutics Market, Global, Apidra, Regulatory Approvals, 2011 369
  • Table 155: Type 2 diabetes Therapeutics Market, Global, Welchol, Clinical Study Details, 2011 372
  • Table 156: Type 2 Diabetes Therapeutics Market, Global, Welchol, Regulatory Approvals, 2011 373
  • Table 157: Type 2 Diabetes Therapeutics Market, Global, Cycloset, Clinical Study Details, 2011 379
  • Table 158: Type 2 Diabetes Therapeutics Market, Global, Bydureon, (DURATION-2) Trial Efficacy, 2011 387
  • Table 159: Type 2 Diabetes Therapeutics Market, Global, Desirable Drug Delivery Methods for Diabetes are Currently Unavailable, 2011 396
  • Table 160: Type 2 Diabetes Therapeutics Market, Regulatory Filing, October 2011 398
  • Table 161: Type 2 Diabetes Therapeutics Market, Global, Phase III Pipeline, October 2011 399
  • Table 162: Type 2 Diabetes Therapeutics Market, Global, Phase II Pipeline, October 2011 400
  • Table 163: Type 2 Diabetes Therapeutics Market, Global, Phase I Pipeline, October 2011 403
  • Table 164: Type 2 Diabetes Therapeutics Market, Global, Preclinical and Discovery Pipeline, October, 2011 406
  • Table 165: Type 2 Diabetes Therapeutics Market, Global, Co-Development Agreements, 2010-2011 443
  • Table 166: Type 2 Diabetes Therapeutics Market, Global, Licensing Agreements, 2010-2011 447
  • Table 167: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Status, October 2011 448
  • Table 168: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Country, October 2011 450
  • Table 169: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Phase, October 2011 451
  • Table 170: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Sponsor Type, October 2011 452
  • Table 171: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials, Leading Sponsors, October 2011 453
  • Table 172: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, October 2011 454
  • Table 173: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, October 2011 455
  • Table 174: Type 2 Diabetes Therapeutics Market, Global, Merger and Acquisition Deals by Geography, 2008-2011 505
  • Table 175:Type 2 Diabetes Therapeutics Market, Global, Merger and Acquisition Deals by Geography, 2011 507
  • Table 176:Type 2 Diabetes Therapeutics Market, Global, Merger and Acquisition Deals by Deal Size, 2011 507

List of Figures

1.2 List of Figures

  • Figure 1: Type 2 Diabetes, Global, Treatment Guidelines, 2011 28
  • Figure 2: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn), 2002-2011 30
  • Figure 3: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn) by Country, 2002-2011 32
  • Figure 4: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2011 34
  • Figure 5: Type 2 Diabetes Therapeutics Market, Global, Patient Volume (million), 2002-2011 36
  • Figure 6: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2011 38
  • Figure 7: Type 2 Diabetes Therapeutics Market, Global, Market Drivers and Restraints, 2011 40
  • Figure 8: Type 2 Diabetes Therapeutics Market, Global, The Impact of Historical Events on the Market, 2011 42
  • Figure 9: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn), 2011-2020 43
  • Figure 10: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn) by Country, 2011-2020 44
  • Figure 11: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2020 46
  • Figure 12: Type 2 Diabetes Therapeutics Market, Global, Patient Volume (million), 2011-2020 48
  • Figure 13: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2020 50
  • Figure 14: Type 2 Diabetes Therapeutics Market, Global, Future Market Drivers and Restraints, 2011-2020 52
  • Figure 15: Type 2 Diabetes Therapeutics Major Markets, Drug Sales ($bn), 2002-2020 53
  • Figure 16: Type 2 Diabetes Therapeutics Market, The US, Sales Value ($bn), 2002-2011 57
  • Figure 17: Type 2 Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2011 58
  • Figure 18: Type 2 Diabetes Therapeutics Market, The US, Patient Volume (million), 2002-2011 60
  • Figure 19: Type 2 Diabetes Therapeutics Market, The US, Treatment Usage Patterns (million), 2002-2011 62
  • Figure 20: Type 2 Diabetes Therapeutics Market, The US, Market Drivers and Restraints, 2011 64
  • Figure 21: Type 2 Diabetes Therapeutics Market, The US, The Impact of Historical Events on the Market, 2011 66
  • Figure 22: Type 2 Diabetes Therapeutics Market, The US, Sales Value ($bn), 2011-2020 67
  • Figure 23: Type 2 Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2011-2020 68
  • Figure 24: Type 2 Diabetes Therapeutics Market, The US, Patient Volume (million), 2011-2020 69
  • Figure 25: Type 2 Diabetes Therapeutics Market, The US, Treatment Usage Patterns (million), 2011-2020 71
  • Figure 26: Type 2 Diabetes Therapeutics Market, The US, Future Market Drivers and Restraints, 2011-2020 73
  • Figure 27: Type 2 Diabetes Therapeutics Market, The US, Drug Sales ($bn), 2002-2020 74
  • Figure 28: Type 2 Diabetes Therapeutics Market, The UK, Sales Value ($m), 2002-2011 79
  • Figure 29: Type 2 Diabetes Therapeutics Market, The UK, Annual Cost of Therapy ($), 2002-2011 80
  • Figure 30: Type 2 Diabetes Therapeutics Market, The UK, Patient Volume (million), 2002-2011 82
  • Figure 31: Type 2 Diabetes Therapeutics Market, The UK, Treatment Usage Patterns (million), 2002-2011 83
  • Figure 32: Type 2 Diabetes Therapeutics Market, The UK, Market Drivers and Restraints, 2011 85
  • Figure 33: Type 2 Diabetes Therapeutics Market, The UK, The Impact of Historical Events on the Market, 2011 87
  • Figure 34: Type 2 Diabetes Therapeutics Market, The UK, Sales Value ($m), 2011-2020 88
  • Figure 35: Type 2 Diabetes Therapeutics Market, The UK, Annual Cost of Therapy ($), 2011-2020 89
  • Figure 36: Type 2 Diabetes Therapeutics Market, The UK, Patient Volume (million), 2011-2020 91
  • Figure 37: Type 2 Diabetes Therapeutics Market, The UK, Treatment Usage Patterns (million), 2011-2020 93
  • Figure 38: Type 2 Diabetes Therapeutics Market, The UK, Future Market Drivers and Restraints, 2011-2020 95
  • Figure 39: Type 2 Diabetes Therapeutics Market, The UK, Drug Sales ($m), 2002-2020 96
  • Figure 40: Type 2 Diabetes Therapeutics Market, Germany, Sales Value ($m), 2002-2011 101
  • Figure 41: Type 2 Diabetes Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002-2011 102
  • Figure 42: Type 2 Diabetes Therapeutics Market, Germany, Patient Volume (million), 2002-2011 104
  • Figure 43: Type 2 Diabetes Therapeutics Market, Germany, Treatment Usage Patterns (million), 2002-2011 106
  • Figure 44: Type 2 Diabetes Therapeutics Market, Germany, Market Drivers and Restraints, 2011 108
  • Figure 45: Type 2 Diabetes Therapeutics Market, Germany, The Impact of Historical Events on the Market, 2011 110
  • Figure 46: Type 2 Diabetes Therapeutics Market, Germany, Sales Value ($m), 2011-2020 111
  • Figure 47: Type 2 Diabetes Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011-2020 112
  • Figure 48: Type 2 Diabetes Therapeutics Market, Germany, Patient Volume (million), 2011-2020 114
  • Figure 49: Type 2 Diabetes Therapeutics Market, Germany, Treatment Usage Patterns (million), 2011-2020 116
  • Figure 50: Type 2 Diabetes Therapeutics Market, Germany, Future Market Drivers and Restraints, 2011-2020 118
  • Figure 51: Type 2 Diabetes Therapeutics Market, Germany, Drug Sales ($m), 2002-2020 119
  • Figure 52: Type 2 Diabetes Therapeutics Market, France, Sales Value ($m), 2002-2011 124
  • Figure 53: Type 2 Diabetes Therapeutics Market, France, Annual Cost of Therapy ($), 2002-2011 125
  • Figure 54: Type 2 Diabetes Therapeutics Market, France, Patient Volume (million), 2002-2011 127
  • Figure 55: Type 2 Diabetes Therapeutics Market, France, Treatment Usage Patterns (million), 2002-2011 128
  • Figure 56: Type 2 Diabetes Therapeutics Market, France, Market Drivers and Restraints, 2011 130
  • Figure 57: Type 2 Diabetes Therapeutics Market, France, The Impact of Historical Events on the Market, 2011 132
  • Figure 58: Type 2 Diabetes Therapeutics Market, France, Sales Value ($m), 2011-2020 133
  • Figure 59: Type 2 Diabetes Therapeutics Market, France, Annual Cost of Therapy ($), 2011-2020 134
  • Figure 60: Type 2 Diabetes Therapeutics Market, France, Patient Volume (million), 2011-2020 135
  • Figure 61: Type 2 Diabetes Therapeutics Market, France, Treatment Usage Patterns (million), 2011-2020 137
  • Figure 62: Type 2 Diabetes Therapeutics Market, France, Future Market Drivers and Restraints, 2011-2020 139
  • Figure 63: Type 2 Diabetes Therapeutics Market, France, Drug Sales ($m), 2002-2020 140
  • Figure 64: Type 2 Diabetes Therapeutics Market, Italy, Sales Value ($m), 2002-2011 145
  • Figure 65: Type 2 Diabetes Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002-2011 146
  • Figure 66: Type 2 Diabetes Therapeutics Market, Italy, Patient Volume (million), 2002-2011 147
  • Figure 67: Type 2 Diabetes Therapeutics Market, Italy, Treatment Usage Patterns (million), 2002-2011 149
  • Figure 68: Type 2 Diabetes Therapeutics Market, Italy, Market Drivers and Restraints, 2011 151
  • Figure 69: Type 2 Diabetes Therapeutics Market, Italy, The Impact of Historical Events on the Market, 2011 153
  • Figure 70: Type 2 Diabetes Therapeutics Market, Italy, Sales Value ($m), 2011-2020 154
  • Figure 71: Type 2 Diabetes Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011-2020 155
  • Figure 72: Type 2 Diabetes Therapeutics Market, Italy, Patient Volume (million), 2011-2020 156
  • Figure 73: Type 2 Diabetes Therapeutics Market, Italy, Treatment Usage Patterns (million), 2011-2020 158
  • Figure 74: Type 2 Diabetes Therapeutics Market, Italy, Future Market Drivers and Restraints, 2011-2020 160
  • Figure 75: Type 2 Diabetes Therapeutics Market, Italy, Drug Sales ($m), 2002-2020 161
  • Figure 76: Type 2 Diabetes Therapeutics Market, Spain, Sales Value ($m), 2002-2011 166
  • Figure 77: Type 2 Diabetes Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002-2011 167
  • Figure 78: Type 2 Diabetes Therapeutics Market, Spain, Patient Volume (million), 2002-2011 168
  • Figure 79: Type 2 Diabetes Therapeutics Market, Spain, Treatment Usage Patterns (million), 2002-2011 169
  • Figure 80: Type 2 Diabetes Therapeutics Market, Spain, Market Drivers and Restraints, 2011 171
  • Figure 81: Type 2 Diabetes Therapeutics Market, Spain, The Impact of Historical Events on the Market, 2011 173
  • Figure 82: Type 2 Diabetes Therapeutics Market, Spain, Sales Value ($m), 2011-2020 174
  • Figure 83: Type 2 Diabetes Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011-2020 175
  • Figure 84: Type 2 Diabetes Therapeutics Market, Spain, Patient Volume (million), 2011-2020 176
  • Figure 85: Type 2 Diabetes Therapeutics Market, Spain, Treatment Usage Patterns (million), 2011-2020 178
  • Figure 86: Type 2 Diabetes Therapeutics Market, Spain, Future Market Drivers and Restraints, 2011-2020 180
  • Figure 87: Type 2 Diabetes Therapeutics Market, Spain, Drug Sales ($m), 2002-2020 181
  • Figure 88: Type 2 Diabetes Therapeutics Market, Japan, Sales Value ($m), 2002-2011 186
  • Figure 89: Type 2 Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2011 187
  • Figure 90: Type 2 Diabetes Therapeutics Market, Japan, Patient Volume (million), 2002-2011 188
  • Figure 91: Type 2 Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (million), 2002-2011 189
  • Figure 92: Type 2 Diabetes Therapeutics Market, Japan, Market Drivers and Restraints, 2011 191
  • Figure 93: Type 2 Diabetes Therapeutics Market, Japan, The Impact of Historical Events on the Market, 2011 193
  • Figure 94: Type 2 Diabetes Therapeutics Market, Japan, Sales Value ($m), 2011-2020 194
  • Figure 95: Type 2 Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2020 195
  • Figure 96: Type 2 Diabetes Therapeutics Market, Japan, Patient Volume (million), 2011-2020 196
  • Figure 97: Type 2 Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (million), 2011-2020 198
  • Figure 98: Type 2 Diabetes Therapeutics Market, Japan, Future Market Drivers and Restraints, 2011-2020 200
  • Figure 99: Type 2 Diabetes Therapeutics Market, Japan, Drug Sales ($m), 2002-2020 201
  • Figure 100: Type 2 Diabetes Therapeutics Market, Brazil, Sales Value ($m), 2002-2011 206
  • Figure 101: Type 2 Diabetes Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002-2011 207
  • Figure 102: Type 2 Diabetes Therapeutics Market, Brazil, Patient Volume (million), 2002-2011 208
  • Figure 103: Type 2 Diabetes Therapeutics Market, Brazil, Treatment Usage Patterns (million), 2002-2011 209
  • Figure 104: Type 2 Diabetes Therapeutics Market, Brazil, Market Drivers and Restraints, 2011 211
  • Figure 105: Type 2 Diabetes Therapeutics Market, Brazil, The Impact of Historical Events on the Market, 2011 213
  • Figure 106: Type 2 Diabetes Therapeutics Market, Brazil, Sales Value ($m), 2011-2020 214
  • Figure 107: Type 2 Diabetes Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011-2020 215
  • Figure 108: Type 2 Diabetes Therapeutics Market, Brazil, Patient Volume (million), 2011-2020 216
  • Figure 109: Type 2 Diabetes Therapeutics Market, Brazil, Treatment Usage Patterns (million), 2011-2020 218
  • Figure 110: Type 2 Diabetes Therapeutics Market, Brazil, Future Market Drivers and Restraints, 2011-2020 220
  • Figure 111: Type 2 Diabetes Therapeutics Market, India, Sales Value ($m), 2002-2011 221
  • Figure 112: Type 2 Diabetes Therapeutics Market, India, Annual Cost of Therapy ($), 2002-2011 222
  • Figure 113: Type 2 Diabetes Therapeutics Market, India, Patient Volume (million), 2002-2011 223
  • Figure 114: Type 2 Diabetes Therapeutics Market, India, Treatment Usage Patterns (million), 2002-2011 224
  • Figure 115: Type 2 Diabetes Therapeutics Market, India, Market Drivers and Restraints, 2011 226
  • Figure 116: Type 2 Diabetes Therapeutics Market, India, The Impact of Historical Events on the Market, 2011 228
  • Figure 117: Type 2 Diabetes Therapeutics Market, India, Sales Value ($m), 2011-2020 229
  • Figure 118: Type 2 Diabetes Therapeutics Market, India, Annual Cost of Therapy ($), 2011-2020 230
  • Figure 119: Type 2 Diabetes Therapeutics Market, India, Patient Volume (million), 2011-2020 231
  • Figure 120: Type 2 Diabetes Therapeutics Market, India, Treatment Usage Patterns (million), 2011-2020 233
  • Figure 121: Type 2 Diabetes Therapeutics Market, India, Future Market Drivers and Restraints, 2011-2020 235
  • Figure 122: Type 2 Diabetes Therapeutics Market, China, Sales Value ($m), 2002-2011 236
  • Figure 123: Type 2 Diabetes Therapeutics Market, China, Annual Cost of Therapy ($), 2002-2011 237
  • Figure 124: Type 2 Diabetes Therapeutics Market, China, Patient Volume (million), 2002-2011 238
  • Figure 125: Type 2 Diabetes Therapeutics Market, China, Treatment Usage Patterns (million), 2002-2011 239
  • Figure 126: Type 2 Diabetes Therapeutics Market, China, Market Drivers and Restraints, 2011 241
  • Figure 127: Type 2 Diabetes Therapeutics Market, China, The Impact of Historical Events on the Market, 2011 243
  • Figure 128: Type 2 Diabetes Therapeutics Market, China, Sales Value ($m), 2011-2020 244
  • Figure 129: Type 2 Diabetes Therapeutics Market, China, Annual Cost of Therapy ($), 2011-2020 245
  • Figure 130: Type 2 Diabetes Therapeutics Market, China, Patient Volume (million), 2011-2020 246
  • Figure 131: Type 2 Diabetes Therapeutics Market, China, Treatment Usage Patterns (million), 2011-2020 248
  • Figure 132: Type 2 Diabetes Therapeutics Market, China, Future Market Drivers and Restraints, 2011-2020 250
  • Figure 133: Type 2 Diabetes Therapeutics Market, Russia, Sales Value ($m), 2002-2011 250
  • Figure 134: Type 2 Diabetes Therapeutics Market, Russia, Annual Cost of Therapy ($), 2002-2011 251
  • Figure 135: Type 2 Diabetes Therapeutics Market, Russia, Patient Volume (million), 2002-2011 253
  • Figure 136: Type 2 Diabetes Therapeutics Market, Russia, Treatment Usage Patterns (million), 2002-2011 254
  • Figure 137: Type 2 Diabetes Therapeutics Market, Russia, Market Drivers and Restraints, 2011 256
  • Figure 138: Type 2 Diabetes Therapeutics Market, Russia, The Impact of Historical Events on the Market, 2011 258
  • Figure 139: Type 2 Diabetes Therapeutics Market, Russia, Sales Value ($m), 2011-2020 259
  • Figure 140: Type 2 Diabetes Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011-2020 260
  • Figure 141: Type 2 Diabetes Therapeutics Market, Russia, Patient Volume (million), 2011-2020 261
  • Figure 142: Type 2 Diabetes Therapeutics Market, Russia, Treatment Usage Patterns (million), 2011-2020 263
  • Figure 143: Type 2 Diabetes Therapeutics Market, Russia, Future Market Drivers and Restraints, 2011-2020 265
  • Figure 144: Type 2 Diabetes Therapeutics Market, Global, Opportunity and Unmet Need, 2011 268
  • Figure 145: Type 2 Diabetes Therapeutics Market, Global, Strategic Competitor Assessment of Major Marketed Drugs, 2011 274
  • Figure 146: Type 2 Diabetes Therapeutics Market, Global, Sales Forecast Split by Drugs, 2002-2020 275
  • Figure 147: Type 2 Diabetes Therapeutics Market, Global, Actos, Life Cycle Management Activities 281
  • Figure 148: Type 2 Diabetes Therapeutics Market, Global, Actos Sales Forecast ($m), 2002-2020 282
  • Figure 149: Type 2 Diabetes Therapeutics Market, Global, Actos, Market Share Analysis (%), 2011 283
  • Figure 150: Type 2 Diabetes Therapeutics Market, Global, Avandia, Sales Forecast ($m), 2002-2020 286
  • Figure 151: Type 2 Diabetes Therapeutics Market, Global, Metformin, Sales Forecast ($m), 2002-2020 289
  • Figure 152: Type 2 Diabetes Therapeutics Market, Global, Metformin, Market Share Analysis (%), 2011 290
  • Figure 153: Type 2 Diabetes Therapeutics Market, Global, Amaryl, Sales Forecast ($m), 2002-2020 294
  • Figure 154: Type 2 Diabetes Therapeutics Market, Global, Amaryl, Market Share Analysis (%), 2011 295
  • Figure 155: Type 2 Diabetes Therapeutics Market, Global, Glyburide Product sales Forecast ($m), 2002-2020 299
  • Figure 156: Type 2 Diabetes Therapeutics Market, Global, Glyburide Products, Market Share Analysis (%), 2011 300
  • Figure 157: Type 2 Diabetes Therapeutics Market, Global, Glipizide Sales Forecast ($m), 2002-2020 302
  • Figure 158: Type 2 Diabetes Therapeutics Market, Global, Glipizide, Market Share Analysis (%), 2011 303
  • Figure 159: Type 2 Diabetes Therapeutics Market, Global, Precose/Glucobay Sales Forecast ($m), 2002-2020 305
  • Figure 160: Type 2 Diabetes Therapeutics Market, Global, Precose/Glucobay, Market Share Analysis (%), 2011 306
  • Figure 161: Type 2 Diabetes Therapeutics Market, Global, Glyset Sales Forecast ($m), 2002-2020 310
  • Figure 162: Type 2 Diabetes Therapeutics Market, Global, Glyset, Market Share Analysis (%), 2011 311
  • Figure 163: Type 2 Diabetes Therapeutics Market, Global, Basen, Sales Forecast ($m), 2002-2020 313
  • Figure 164: Type 2 Diabetes Therapeutics Market, Global, Januvia, Mechanism of Action, 2011 314
  • Figure 165: Type 2 Diabetes Therapeutics Market, Global, Januvia, Chemical Structure, 2011 314
  • Figure 166: Type 2 Diabetes Therapeutics Market, Global, Januvia, Life Cycle Management Activities 320
  • Figure 167: Type 2 Diabetes Therapeutics Market, Global, Januvia Product sales Forecast ($m), 2006-2020 321
  • Figure 168: Type 2 Diabetes Therapeutics Market, Global, Januvia, Market Share Analysis (%), 2011 322
  • Figure 169: Type 2 Diabetes Therapeutics Market, Global, Onglyza, Chemical Structure, 2011 323
  • Figure 170: Type 2 Diabetes Therapeutics Market, Global, Onglyza, Life Cycle Management Activities 325
  • Figure 171: Type 2 Diabetes Therapeutics Market, Global, Onglyza Product sales Forecast ($m), 2009-2020 326
  • Figure 172: Type 2 Diabetes Therapeutics Market, Global, Onglyza, Market Share Analysis (%), 2011 327
  • Figure 173: Type 2 Diabetes Therapeutics Market, Global, Galvus, Chemical Structure, 2011 328
  • Figure 174: Type 2 Diabetes Therapeutics Market, Global, Galvus, Life Cycle Management Activities 331
  • Figure 175: Type 2 Diabetes Therapeutics Market, Global, Galvus Sales Forecast ($m), 2007-2020 332
  • Figure 176: Type 2 Diabetes Therapeutics Market, Global, Galvus, Market Share Analysis (%), 2011 333
  • Figure 177: Type 2 Diabetes Therapeutics Market, Global, Starlix Sales Forecast ($m), 2002-2020 335
  • Figure 178: Type 2 Diabetes Therapeutics Market, Global, Starlix, Market Share Analysis (%), 2011 336
  • Figure 179: Type 2 Diabetes Therapeutics Market, Global, Byetta, Chemical Structure, 2011 337
  • Figure 180: Type 2 Diabetes Therapeutics Market, Global, Byetta, Life Cycle Management Activities 340
  • Figure 181: Type 2 Diabetes Therapeutics Market, Global, Byetta Sales Forecast ($m), 2005-2020 341
  • Figure 182: Type 2 Diabetes Therapeutics Market, Global, Byetta, Market Share Analysis (%), 2011 342
  • Figure 183: Type 2 Diabetes Therapeutics Market, Global, Victoza, Chemical Structure, 2011 343
  • Figure 184: Type 2 Diabetes Therapeutics Market, Global, Victoza, Life Cycle Management Activities 346
  • Figure 185: Type 2 Diabetes Therapeutics Market, Global, Victoza Sales Forecast ($m), 2009-2020 347
  • Figure 186: Type 2 Diabetes Therapeutics Market, Global, Victoza, Market Share Analysis (%), 2011 348
  • Figure 187: Type 2 Diabetes Therapeutics Market, Global, Lantus, Chemical Structure, 2011 349
  • Figure 188: Type 2 Diabetes Therapeutics Market, Global, Lantus, Life Cycle Management Activities 350
  • Figure 189: Type 2 Diabetes Therapeutics Market, Global, Lantus Sales Forecast ($m), 2002-2020 351
  • Figure 190: Type 2 Diabetes Therapeutics Market, Global, Lantus, Market Share Analysis (%), 2011 351
  • Figure 191: Type 2 Diabetes Therapeutics Market, Global, Levemir, Chemical Structure, 2011 352
  • Figure 192: Type 2 Diabetes Therapeutics Market, Global, Levemir, Life Cycle Management Activities 353
  • Figure 193: Type 2 Diabetes Therapeutics Market, Global, Levemir Sales Forecast ($m), 2004-2020 354
  • Figure 194: Type 2 Diabetes Therapeutics Market, Global, Levemir, Market Share Analysis (%), 2011 355
  • Figure 195: Type 2 Diabetes Therapeutics Market, Global, Humalog Sales Forecast ($m), 2002-2020 358
  • Figure 196: Type 2 Diabetes Therapeutics Market, Global, Humalog, Market Share Analysis (%), 2011 359
  • Figure 197: Type 2 Diabetes Therapeutics Market, Global, Humulin Sales Forecast ($m), 2002-2020 361
  • Figure 198: Type 2 Diabetes Therapeutics Market, Global, Humulin, Market Share Analysis (%), 2011 362
  • Figure 199: Type 2 Diabetes Therapeutics Market, Global, Novolog Sales Forecast ($m), 2002-2020 365
  • Figure 200: Type 2 Diabetes Therapeutics Market, Global, Novolog, Market Share Analysis (%), 2011 366
  • Figure 201: Type 2 Diabetes Therapeutics Market, Global, Apidra, Sales Forecast ($m), 2004-2020 369
  • Figure 202: Type 2 Diabetes Therapeutics Market, Global, Apidra, Market Share Analysis (%), 2011 370
  • Figure 203: Type 2 Diabetes Therapeutics Market, Global, Welchol Sales Forecast ($m), 2008-2020 373
  • Figure 204: Type 2 Diabetes Therapeutics Market, Global, Nesnia Sales Forecast ($m), 2010-2020 377
  • Figure 205: Type 2 Diabetes Therapeutics Market, Global, Cycloset Sales Forecast ($m), 2010-2020 379
  • Figure 206: Type 2 Diabetes Therapeutics Market, Global, Tradjenta, Chemical Structure, 2011 380
  • Figure 207: Type 2 Diabetes Therapeutics Market, Global, Tradjenta Sales Forecast ($m), 2011-2020 384
  • Figure 208: Type 2 Diabetes Therapeutics Market, Global, Bydureon Sales Forecasts ($m), 2011-2020 388
  • Figure 209: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Phase of Development (%), 2011 390
  • Figure 210: Type 2 Diabetes Therapeutics Market, Global, Pipeline by Mechanism of Action, 2011 391
  • Figure 211: Type 2 Diabetes Therapeutics Market Pipeline, Phase of Clinical Development, 2011 392
  • Figure 212: Type 2 Diabetes Therapeutics Market, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2011 393
  • Figure 213: Type 2 Diabetes Therapeutics Market, Global, Technology Trends Description of Pipeline Drugs, 2011 393
  • Figure 214: Type 2 Diabetes Therapeutics Market, Global, Lixisenatide Sales Forecast ($m), 2013-2020 411
  • Figure 215: Type 2 Diabetes Therapeutics Market, Global, Syncria Sales Forecast ($m), 2014-2020 413
  • Figure 216: Type 2 Diabetes Therapeutics Market, Global, Degludec Sales Forecast ($m), 2013-2020 416
  • Figure 217: Type 2 Diabetes Therapeutics Market, Global, Dapagliflozin, Chemical Structure, 2011 416
  • Figure 218: Type 2 Diabetes Therapeutics Market, Global, Dapagliflozin Sales Forecast ($m), 2012-2020 419
  • Figure 219: Type 2 Diabetes Therapeutics Market, Global, Canagliflozin, Chemical Structure, 2011 419
  • Figure 220: Type 2 Diabetes Therapeutics Market, Global, Canagliflozin Sales Forecast ($m), 2013-2020 421
  • Figure 221: Type 2 Diabetes Therapeutics Market, Global, Empagliflozin Sales Forecast ($m), 2014-2020 424
  • Figure 222: Type 2 Diabetes Therapeutics Market, Global, Ipragliflozin, Chemical Structure, 2011 425
  • Figure 223: Type 2 Diabetes Therapeutics Market, Global, Ipragliflozin Sales Forecast ($m), 2014-2020 426
  • Figure 224: Type 2 Diabetes Therapeutics Market, Global, Aleglitazar, Chemical Structure, 2011 427
  • Figure 225: Type 2 Diabetes Therapeutics Market, Global, Aleglitazar Sales Forecast ($m), 2017-2020 428
  • Figure 226: Type 2 Diabetes Therapeutics Market, Global, Dulaglutide Sales Forecast ($m), 2014-2020 431
  • Figure 227: Type 2 Diabetes Therapeutics Market, Global, D-Tagatose, Chemical Structure, 2011 431
  • Figure 228: Type 2 Diabetes Therapeutics Market, Global, Naturlose Sales Forecast ($m), 2012-2020 433
  • Figure 229: Type 2 Diabetes Therapeutics Market, Global, Licensing Agreements by Phase of Development (%), 2011 443
  • Figure 230: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Status, October 2011 448
  • Figure 231: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Country, October 2011 449
  • Figure 232: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Phase, October 2011 450
  • Figure 233: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Sponsor Type, October 2011 451
  • Figure 234: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials, Leading Sponsors, October 2011 452
  • Figure 235: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, October 2011 453
  • Figure 236: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, October 2011 454
  • Figure 237: Type 2 Diabetes, Global, Key Events Impacting the Future Market, 2011 455
  • Figure 238: Type 2 Diabetes Therapeutics Market, Global, Implications for Future Market Competition, 2011 457
  • Figure 239: Type 2 Diabetes, Clinical Pipeline by Company, 2011 459
  • Figure 240: Type 2 Diabetes, Novo Nordisk, SWOT Analysis 2011 460
  • Figure 241: Type 2 Diabetes, Amylin Pharmaceuticals, SWOT Analysis 2011 464
  • Figure 242: Type 2 Diabetes, Takeda Pharmaceuticals, SWOT Analysis 2011 468
  • Figure 243: Type 2 Diabetes, Boehringer Ingelheim, SWOT Analysis 2011 471
  • Figure 244: Type 2 Diabetes, Eli Lilly and Company, SWOT Analysis 2011 473
  • Figure 245: Type 2 Diabetes, GlaxoSmithKline, SWOT Analysis 2011 477
  • Figure 246: Type 2 Diabetes, Novartis AG., SWOT Analysis 2011 480
  • Figure 247: Type 2 Diabetes, Sanofi, SWOT Analysis 2011 483
  • Figure 248: Type 2 Diabetes, F.Hoffmann La Roche, SWOT Analysis 2011 486
  • Figure 249: Type 2 Diabetes, Bristol-Myers Squibb, SWOT Analysis 2011 488
  • Figure 250: Type 2 Diabetes, Johnson & Johnson, SWOT Analysis 2011 491
  • Figure 251: Type 2 Diabetes, Astellas, SWOT Analysis 2011 499
  • Figure 252: Type 2 Diabetes, Global, Key Data Inputs from KOL Interviews, April 2011 507
  • Figure 253: GlobalData Market Forecasting Model 514
Show More
Pricing
Not Available